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A mutation equivalent to P102L in the human PrP
gene, associated with Gerstmann–Straussler syndrome
(GSS), has been introduced into the murine PrP gene
by gene targeting. Mice homozygous for this muta-
tion (101LL) showed no spontaneous transmissible
spongiform encephalopathy (TSE) disease, but had
incubation times dramatically different from wild-type
mice following inoculation with different TSE sources.
Inoculation with GSS produced disease in 101LL mice
in 288 days. Disease was transmitted from these mice
tobothwild-type(226days)and101LLmice(148days).
In contrast, 101LL mice infected with ME7 had pro-
longed incubation times (338 days) compared with
wild-type mice (161 days). The 101L mutation does
not, therefore, produce any spontaneous genetic disease
in mice but signiﬁcantly alters the incubation time of
TSE infection. Additionally, a rapid TSE transmission
was demonstrated despite extremely low levels of
disease-associated PrP.
Keywords: gene targeting/prion diseases/PrP mutations/
spontaneous prion disease/transmissible spongiform
encephalopathies
Introduction
Transmissible spongiform encephalopathies (TSEs) are a
group of fatal neurodegenerative diseases that are also
infectious. It has been hypothesized that these diseases
are attributable to a conformational change in the prion
protein (PrP), which results in a change from a pre-
dominantly α-helical protein to a β-sheet form (Prusiner,
1996; Weissmann, 1996). PrP, which is converted from
the normal cellular form of the protein (PrPC) to the
protease-resistant, disease-speciﬁc form (PrPSc) during the
infectious process (Prusiner, 1991), has been proposed to
be the infectious agent (Grifﬁth, 1967). The prion hypo-
thesis predicts that PrPSc can propagate its own conversion
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by acting as a template or a seed (Jarrett and Lansbury,
1993), allowing further conversion of PrPC to PrPSc
to occur.
Polymorphisms at amino acids 108 and 189 in the
murine PrP gene have a major inﬂuence on incubation time
of scrapie in mice (Moore et al., 1998). Polymorphisms at
amino acids 129 and 219 are associated with altered
incubation time or susceptibility to human TSEs (Palmer
et al, 1991; Goldfarb et al., 1992). Polymorphisms at
amino acids 136 and 171 in the PrP gene are associated
with susceptibility to TSE disease in sheep (Goldmann
et al., 1994). The mechanism by which these mutations
lead to altered susceptibility or incubation periods has not
been deﬁned, but it has been proposed that the human
polymorphisms may be present in a site involved in the
conformational transition from PrPC to PrPSc (Glockshuber
et al., 1999).
In vitro assay systems (Priola et al., 1994) and mouse
models (Scott et al., 1992) have suggested that homology
between an infectious and endogenous PrP molecule
facilitates the efﬁcient conversion of PrPC to PrPSc,
allowing TSE disease to develop in the host. By introdu-
cing an appropriate PrP gene into transgenic mice, the
species barrier can be overcome, as demonstrated with
transgenic mice expressing a hamster PrP gene, which
were shown to be susceptible to hamster strains of scrapie,
in contrast to wild-type mice (Scott et al., 1989).
While the above mutations alter the susceptibility of an
animal following exposure toan infectious agent, a number
of point mutations and insertions in the human PrP gene
apparently lead to spontaneous genetic disease (Prusiner,
1997; Parchi et al., 1998), many of which have been
transmitted subsequently to rodents and primates (Tateishi
and Kitamoto, 1995; Young et al., 1999). It has been
suggested that inherited human TSEs result from mutations
in the PrP gene leading to amino acid changes that
destabilize the three-dimensional structure of the PrP
protein (Cohen et al., 1994; Huang et al., 1994; Harrison
et al., 1997) and that this inherent instability makes the
PrPC protein more likely to convert to and accumulate as
PrPSc. A transgenic mouse overexpressing a murine PrP
gene with a Leu101 mutation was shown to develop
disease spontaneously (Hsiao et al., 1990; Telling et al.,
1996), suggesting that the 101L mutation may indeed
result in an unstable PrP protein. In addition, the resultant
spontaneous disease was transmitted to transgenic mice
expressing the same transgene but not to wild-type mice
(Hsiao et al., 1994), suggesting a requirement for homo-
logy between PrP molecules for transmission of the disease
to occur.
PrP has also been implicated in the pathological process
leading to neurodegeneration. PrPSc accumulates in the
brain during disease, but grafting tissue from wild-type
mice into the brain of PrP null mice has shown thatJ.C.Manson et al.
accumulation of PrPSc is not sufﬁcient to lead to the
development of pathology in the brain in the absence of
PrPC (Brandner et al., 1996). PrPSc accumulation has not
been detected in all TSE disease. Although PrP accumu-
lates in the brains of the 101 transgenic mice described
above, it does not have the characteristic protease resist-
ance associated with PrPSc (Hsiao et al., 1990; Telling
et al., 1996). Primary transmission of bovine spongiform
encephalopathy (BSE) agent to mice has been described
in the apparent absence of PrPSc accumulation (Lasmezas
et al., 1997). Spontaneous neurodegenerative disease has
also been reported in transgenic mice with an AV3
substitution in PrP in which an abnormal transmembrane
form of PrP protein accumulates rather than PrPSc (Hedge
et al., 1998), although transmissibility of disease from
these mice has not been reported.
Although certain mutations in PrP have been shown to
alter the incubation period of TSE disease (Moore et al.,
1998), the mechanism by which this effect is achieved
has not been deﬁned. Here we describe the introduction
of a 101L mutation into the endogenous murine PrP
gene. This mutation does not lead to the development of
spontaneous TSE disease in these mice, but dramatically
alters the incubation times of disease following exposure
of the 101LL mice to different strains of agent. One of
the resulting TSE diseases can be transmitted to both
wild-type and mutant mice with short incubation periods,
despite extremely low amounts of PrPSc in the inoculum.
Results
Gene expression from the Prnpa101 allele
A two-step double replacement gene targeting strategy
was used to alter Prnpaexon 3 in HM-1, a 129/Ola murine
embryonic stem cell line. Gene targeting was used to alter
speciﬁcally amino acid 101 (equivalent to amino acid 102
in human PrP) from the wild-type proline (101P) residue
to a leucine (101L), to generate in situ a modiﬁed Prnpa
allele expressing the mutant PrP gene (Moore et al., 1995).
The targeted allele has been designated Prnptm1Edinreferred
to in this text by the more descriptive name Prnpa101L
(Figure 1A). HM-1 embryonic stem (ES) clones carrying
a Prnpa101L mutant allele were used to produce chimeric
mice (Moore et al., 1995). A chimera, which transmitted
the mutant allele, was used to generate progeny heterozy-
gous for the Prnpa101L allele (101PL), which were then
inter-bred to produce progeny homozygous for the
Prnpa101L allele (101LL). Wild-type mice are referred to
as 101PP.
The structure of the targeted Prnpa101L allele in the
mice was investigated by Southern blot analysis
(Figure 1B) using probes derived from intron 2 and exon
3 (Figure 1A). The 101L mutation changes CCC-Pro to
CTC-Leu, creating an additional DdeI site within exon 3.
No other alteration was detected in the targeted allele.
The entire Prnp coding region from the 101LL mice was
sequenced to conﬁrm that no mutations, other than the
desired one, had been introduced during the construction
of the mice (data not shown). These studies conﬁrm that
the Prnpa101L allele has undergone no detectable deletions,
insertions or rearrangements during the gene targeting
process or during the production of the mice. The 101PL
mice were crossed with CB20 mice to produce an outbred
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Fig. 1. (A) Gene structure and gene expression from the Prnpa101L
allele. Restriction map of the wild-type 129/Ola Prnpa allele and the
targeted Prnpa101L alleles. Probes are shown as hatched boxes. The
Prnpa allele yields 151 and 613 bp DdeI exon 3 fragments and the
Prnpa101L allele yields 464, 151 and 149 bp DdeI fragments from
exon 3 due to the additional DdeI site created by the mutation. The
following Prnp probes were used: probe a, a 884 bp PCR product of
intron 2 from 25 004 to 25 887 bp (DDBJ/EMBL/GenBank accession
No. U29186); probe b, a 936 bp KpnI–EcoRI fragment from exon 3;
and probe c, a 700 bp EcoRV–BamHI fragment at the 3 end of the
Prnp gene. Abbreviations: BamHI (B), XbaI( X ) ,DdeI( D ) ,EcoRV
(RV), E1, exon 1; E2, exon 2; E3, exon 3. (B) Genomic Southern
analysis of the Prnpa101L allele. Genomic DNA was isolated from
101LL and 101PP mice and digested with KpnI( K ) ,BamHI (B),
EcoRI (E), HindIII (H), XbaI (X) and BstEII (Bs). Following
digestion, the fragments were separated on a 1% agarose gel blotted
on to Genescreen plus (Dupont) and hybridized with probe c (3 end
of the Prnp gene) and probe a (5 end of the Prnp gene). These data,
together with exon 3 nucleic acid sequence (data not shown), conﬁrm
that the targeted Prnpa101L allele is indistinguishable from the parental
129/Ola Prnpa allele, with the exception of the engineered PrP codon
101L alteration. (C) Northern analysis of PrP mRNA in the brain.
Total brain RNA (20 µg) probed with a 936 bp KpnI–EcoRI mouse
PrP exon 3 DNA probe. Lanes 1 and 2, wild-type 129/Ola (101PP);
lane 3, heterozygous PrP null (101P/–) to demonstrate that a 50%
reduction in mRNA was detectable; lane 4, PrP–/–; lanes 5–7, mice
with two copies of the targeted Prnpa101L allele (101LL); lane 8, mice
with one copy of the Prnpa101L allele and a null allele (101L/–).
Mouse 18S rRNA reprobe of the membrane. Quantitation of the 18S
rRNA signal was determined using PhosphorImager technology
(Molecular Dynamics), and these values were used to correct for
loading variations. (D) Western blots of crude brain homogenates from
mice expressing wild-type Prnpa and gene-targeted Prnpa101L alleles.
Samples were resolved on SDS–PAGE and transferred to PVDF
membrane. PrP was detected with a rabbit anti-mouse PrP polyclonal
serum 1A8 (top) or mouse monoclonal 8H4 (bottom) and visualized
with either HRP-conjugated goat anti-rabbit or rabbit anti-mouse
secondary antibodies and a chemiluminesence detection kit.
Lanes 1–5, mouse with two copies of the Prnpa101L allele (101LL);
lanes 7–11, wild-type mouse (101PP). Lanes 1 and 7, 100 µg; lanes 2
and 8, 75 µg; lanes 3 and 9, 50 µg; lanes 4 and 10, 25 µg; and lanes 5
and 11, 1 µg wet weight tissue equivalents.101L PrP mutation and TSE disease
line of mice with the mutant allele as well as being
maintained on an inbred 129/Ola background. All TSE
inoculation experiments were carried out using inbred
mice.
The level of expression of the PrP gene from the
targeted allele (Prnpa101L) was assessed and compared
with the wild-type gene. Northern blot analysis detected
similar levels of PrP mRNA in mice with the mutant
Prnpa101L allele (101LL) and in wild-type mice (101PP)
(Figure 1C). Western blot analysis using both monoclonal
and polyclonal PrP antibodies, however, has indicated that
the steady-state level of the PrP protein in 101LL mice is
apparently lower than that in wild-type mice (Figure 1D).
Accurate quantiﬁcation of the difference in amount of PrP
between the two lines of mice has proved difﬁcult by
Western blot analysis, but a more quantitative assay system
is being developed to address this question. This reduction
in PrP in 101LL mice may be a result of altered processing
or stability of the mutant protein. Alternatively, altered
conformation may lead to differences in the ability of the
antibodies to bind to the mutant PrP protein and thus lead
to an apparent reduction in the protein levels detected.
The different PrP protein levels in the 101LL mice most
probably result directly from the 101L mutation, which
has been introduced into the murine gene, since sequencing
and Southern blot analysis of the PrP gene did not detect
any differences between the 101LL and 101PP mice
except for the 101L mutation. Additional evidence that
suggests that the alteration in PrP protein level may be a
speciﬁc effect of the 101L mutation is provided by
the previous gene targeting experiments in which we
introduced alterations into amino acids L108F and T189V.
Mice with these alterations were shown to have levels of
PrP mRNA and protein identical to the wild-type mice
(Moore et al., 1998). Why this mutation should lead to
an altered level of PrP is currently under investigation,
but for the purposes of assessing TSE incubation times in
the 101LL and 101PL mice reported here, it is important
to allow for the apparent reduction in level of PrP protein
in the 101LL mice. This is because it has been shown
that mice with only one copy of the wild-type PrP gene,
and thus with reduced levels of PrP protein, have longer
incubationtimesthanwild-typemicefollowinginoculation
with different strains of TSE (Manson et al., 1994).
The Prnpa101L allele is not sufﬁcient for
spontaneous neurodegenerative disease
Both inbred and outbred mice (200 animals) carrying
one or two copies of the Prnpa101L allele showed no
clinical signs of TSE disease up to 899 days of age (63 of
which were 700 days old). The brains of all culled mice
have been examined for pathological signs of subclinical
TSE. Animals over 350 days showed some vacuolation
limited to white matter regions of the brain, consistent
with ageing vacuolation and typical of control groups.
In order to assess whether there had been any accumula-
tion of PrP in the brain, despite the absence of clinical
signs of disease, brains from 27 mice both homozygous
and heterozygous for the Prnpa101L allele (631–888 days
old) were examined by immunocytochemical and Western
blot analysis. No PrP deposition was detected in the brains
by immunocytochemical analysis (not shown) and no
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PrPSc was detected by Western blot analysis after long
exposure times of immunoblot to X-ray ﬁlm (Figure 6A).
Brains from mice homozygous for the Prnpa101L allele
were used as an inoculum to assess whether, despite the
absence of clinical or pathological signs of TSE, they
carried spontaneously and endogenously generated TSE
infectivity. A pool of three brains from mice (101LL)
over 700 days old was inoculated intracerebrally into
homozygous (101LL), heterozygous (101PL) and wild-
type 129Ola (101PP) mice. At the time of writing, these
mice have shown no clinical signs of TSE disease
(600 days after inoculation).
The 101L mutation alters the incubation time of
TSE disease
Inbred 129/Ola mice carrying no (101PP), one (101PL)
or two (101LL) copies of the Prnpa101L allele were
inoculated with brain homogenate from a patient who died
of Gerstmann–Straussler syndrome (GSS) (Table I). The
entire coding region of the PrP gene of this patient was
sequenced and was shown to be heterozygous for the
102L mutation, homozygous for 129M and carried no
other mutation in the PrP gene. Only one of eight wild-
type mice showed clinical signs of disease 456 days after
inoculation. Vacuolation was apparent in the cerebellar
and midbrain white matter regions in the brain of this
mouse, but no signiﬁcant grey matter vacuolation was
detected. The remaining seven wild-type mice showed no
signs of clinical disease or signiﬁcant vacuolar pathology
in either white or grey matter regions of the brain up to
701 days post-infection. The brains of these mice were
also devoid of PrP by immunocytochemical analysis and
noPrPScwasdetectedbyWesternblotanalysis(Figure6B).
MicecarryingtwocopiesofthePrnpa101Lallele(101LL)
all developed clinical signs of disease and were culled
between 254 and 317 days after infection. The clinical
phase extended over 4–6 weeks and included ataxia, hind
limb paralysis and marked kyphosis. Vacuolar pathology
of both grey and white matter was evident in the brains
of these mice (Figure 2A). After extensive immunocyto-
chemical analysis of sections at different levels throughout
the brain, using two different polyclonal antibodies (1B3
and 1A8), abnormal accumulation of PrP could not be
detected in ﬁve of the brains (Figure 3B, Table II). This
was despite the fact that all cases had marked vacuolation
in the thalamus, septum and hypothalmus and severe white
matter vacuolation of the midbrain and cerebellar regions.
Minor diffuse deposits of PrP were detected in ﬁve other
cases, restricted to the thalamus and inner cortical layer.
Two of these cases also showed aggregates of PrP in the
corpus callosum near the site of injection, perhaps due to
retention of inoculum in this region.
Although no PrP deposition was detected immunohisto-
chemically in ﬁve of the 101LL mice, the analysis may
not have been sensitive enough to detect very low levels
of PrP in the brain. The histochemical processes required
here for the treatment of the tissues (e.g. formic acid
treatment) have been reported to lead to a loss of PrPC
from some tissues (Kitamoto et al., 1991) and may also
lead to some loss of PrPSc. Western blot analysis of the
brains of the 101LL mice infected with GSS readily
detected PrPC. Polyclonal antisera did not detect any
protease-resistant PrP in these brains on Western blotsJ.C.Manson et al.
Table I. Incubation time of disease following inoculation with GSS, GSSLL and ME7
Inoculum Mouse No. with No. without Incubation time
strain clinical TSE clinical TSE  SEM
GSS (10–1) 101PP 0 1
101PL 4 0 479  29
101LL 2 0 254  0
GSS (10–2) 101PP 1 6 456
101PL 10 8 450  12
101LL 15 0 288  4
GSSLL (10–2) 101PP 16 0 226  3
101PL 20 0 201  3
101LL 18 0 148  2
ME7 (10–2) 101PP 10 0 161  2
101PL 29 0 353  4
101LL 18 0 338  8
Mice with no (101PP), one (101PL) and two (101LL) copies of the Prnpa101L allele were inoculated with primary GSS (GSS), GSS passed through a
101LL mouse (GSSLL) and ME7. The inoculum was injected intracerebrally at 10–1 or 10–2 dilution.
Fig. 2. Mice with one and two copies of the Prnpa101L allele and wild-
type mice were inoculated with brain homogenate from: (A)aG S S
patient with the 102L mutation; (B) a 101LL mouse terminally
infected with GSS; (C) ME7. The extent of vacuolar change in the
brain was assessed semi-quantitatively in nine areas of grey matter and
three of white matter by lesion proﬁling as described (Fraser and
Dickinson, 1967, 1968). Circles (green) are lesion proﬁles of mice at
the terminal stages of disease with one copy of the gene-targeted allele
Prnpa101L (101PL), triangles (red) are mice with two copies of the
Prnpa101L allele (101LL) and diamonds (blue) are wild-type (101PP)
mice. Lesion proﬁles were constructed (using a minimum of
10 animals in each group) on a scale of 0–5, and mean scores for each
area are shown graphically (error bars  SEM). Note: lesion scores
without error bars represent scoring areas where there was no variation
in lesion scores. Lesion proﬁle scoring areas: grey matter areas:
1, dorsal medulla; 2, cerebellar cortex; 3, superior colliculus;
4, hypothalamus; 5, medial thalamus; 6, hippocampus; 7, septum;
8, cerebral cortex; 9, forebrain cerebral cortex. White matter areas:
1*, cerebellar white matter, 2*, midbrain white matter 3*, cerebral
peduncle.
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Fig. 3. Mice with one and two copies of the Prnpa101L allele and wild-
type mice were inoculated with brain homogenate from a GSS patient
with the 102L mutation. The brains of the animals were examined
either at the terminal stage of the disease for animals which developed
TSE disease or at the end of their lifespan for animals with no clinical
signs of disease. PrP deposition in the hippocampus and thalamus
detected by immunocytochemical analysis using two polyclonal
antibodies 1A8 (not shown) and 1B3 (Farquhar et al., 1989). (A) PrP
was detected in the thalamus of 101PL mice inoculated with GSS in
both clinically positive and negative (as shown here at 639 days)
animals, but (B) was barely detectable at the terminal stage of disease
(254 days) in 101LL mice inoculated with GSS. Bar, 100 µm.
(data not shown). However, use of a monoclonal antibody
(8H4) and prolonged exposure times of the immunoblot
to X-ray ﬁlm did detect very low levels of protease-
resistant PrP in the 101LL GSS-infected mice (Figure 6B).
This protease-resistant PrP was not present in uninfected
or aged 101LL mice after similarly long exposure times
and was also not detected in PrP null mice (Figure 6B).101L PrP mutation and TSE disease
Table II. PrP deposition detected by immunocytochemistry in GSS
primary transmission
Mouse No. Clinical TSE Vacuolar PrP deposition
genotype pathology
101PP 7 –––
101PP 1  ––
101PL 1 –––
101PL 1 ––




Mice with no (101PP), one (101PL) and two (101LL) copies of the
Prnpa101L allele inoculated with infectious material from a patient with
GSS were examined for PrP accumulation by immunocytochemistry
using two polyclonal antibodies (1B3 and 1A8). The amount of PrP
deposited in the positive 101PL cases was variable. Only very low
levels of PrP were detected in the positive 101LL cases.
It is therefore likely to represent extremely low levels of
PrPSc in the infected brains. Accumulation of disease-
speciﬁc PrP does not appear to be a signiﬁcant feature of
the TSE pathology in this experimental model.
Mice carrying one copy of the wild-type and one copy
of the mutant allele (101PL) varied considerably in terms
of clinical and pathological TSE (Tables I and II). One
group showed no clinical signs of TSE disease (death
between 537 and 701 days from other causes) and had no
signiﬁcant vacuolar pathology; a second group showed no
clinical signs of disease (death between 537 and 646 days
from other causes) but had signiﬁcant grey and white
matter vacuolation. A third group developed TSE disease
between 411 and 540 days and had severe vacuolation in
grey and white matter regions (Figure 2A). Immunocyto-
chemical analysis of clinically negative 101PL mice
revealed one animal with no detectable PrP and one with
PrP deposition. All clinically positive mice showed PrP
immunostaining. The amount of PrP deposited in the
101PL mice varied from minor cortical PrP to severe
deposition throughout the thalamus and cortex and did
not appear to relate to the clinical status of the animals
(Figure 3A, Table II). PrPSc was detected by Western blot
analysis in all clinically positive 101PL mice inoculated
with GSS but not in the two clinically negative animals
examined (Figure 6B).
In mice with only one copy of the mutant gene (101PL),
the incubation period of disease is less constant than in
the homozygous mice (101LL). Prolonged and variable
incubation periods in the heterozygous mice may reﬂect
a copy number effect, with a single copy of the mutant
gene leading to longer incubation times. The presence of
the wild-type gene in these mice may be interfering with
the disease process associated with the mutant allele. The
mutant allele (Prnpa101L) has now been crossed on to a
PrP null background so that the effect of a single copy of
the mutant gene can be assessed in the absence of the
wild-type gene.
Disease can be transmitted from a GSS-infected
101LL mouse to mice with or without the
Prnpa101L allele
A brain homogenate was prepared from a 101LL mouse
infectedwithGSSthat hadbeenculledattheterminalstage
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of disease (254 days) with no apparent PrP deposition. The
brain used to prepare the inoculum is that shown in
Figure 3B. The inoculum (GSSLL) was injected intra-
cerebrally into mice of the three genotypes (101PP, 101PL
and 101LL). Disease was transmitted to all three groups
of animals, with homozygous 101LL mice having the
shortest incubation period. Signiﬁcantly, even the wild-
type (101PP) mice developed TSE disease within 226 days
(Table I). Thus despite the failure to detect any PrP
accumulation by immunohistochemical analysis and the
extremely low levels of protease-resistant PrP detected by
Western blot analysis in the brains of 101LL mice infected
with GSS, the GSSLL inoculum prepared from it was
able to transmit TSE disease rapidly to mice both with
and without the 101L mutation.
Similar patterns and levels of vacuolation were detected
in the brains of mice of all three genotypes, with particu-
larly high levels being present in white matter areas such
as the cerebellum and cerebral peduncle (Figures 2B and
4A). The heterozygous animals tended to have slightly
higher scores in a number of regions and the wild-type
mice had considerably less vacuolation in the hypothal-
amus (region 4) than the other groups (Figure 2B).
In contrast to the uniformity of vacuolation, the depos-
ition of PrP in the three genotypes of mice showed marked
differences (Figure 4B). The most striking areas of PrP
deposition were the thalamic dorsal lateral geniculate
nuclei and the corpus callosum and subcallosal regions.
The wild-type mice showed marked PrP immunoreactivity
in the thalamus and in the corpus callosum. The hetero-
zygous animals showed variable PrP immunoreactivity
patterns in the thalamus, ranging from low to moderate
levels of PrP deposition. Grainy PrP deposits were present
in the stratum radiatum coupled with diffuse PrP immuno-
reactivity throughout the entire hippocampus.
In contrast to the primary GSS infection of 101LL
mice, PrP accumulation was evident in most of the 101LL
mice inoculated with GSSLL (Figure 4B). All but one
case showed deposition of PrP throughout the thalamic
region. Diffuse deposits of PrP were also detected in the
stratum radiatum and four cases also showed diffuse PrP
coupled with clusters of aggregates throughout the corpus
callosum. There was marked variation in the amount of
PrP detected; one case showed only minor diffuse PrP
immunoreactivity limited to a small focal area of the
thalamus, while another with an incubation period of only
1 day more had extensive PrP accumulation. PrPSc was
detected by Western blot analysis in extracts from all three
groups of animals, although it appeared to vary in quantity,
with less being detected in the 101LL mice than in the
other two groups (101PP and 101PL) (Figure 6C).
101LL mice have long incubation times with ME7
Inoculation with a murine strain of scrapie, ME7, produced
long incubation periods in mice with one (101PL) and
two (101LL) copies of the Prnpa101L gene compared with
the wild-type mice (101PP) (Table I). Although there was
overlap between the incubation periods of heterozygous
(101PL) and homozygous (101LL) mutant mice, the
incubation periods in heterozygous mice tended to be
longer than in homozygous mice. This is similar to the
effects seen in the F1 progeny of crosses between strains
of wild-type mice differing in their Prnp alleles whenJ.C.Manson et al.
Fig. 4. Disease can be transmitted from GSS-affected 101LL mice with no detectable PrP accumulation. Mice with one and two copies of the
Prnpa101L allele and wild-type mice were inoculated with brain homogenate from 101LL mice infected with GSS (the brain used for inoculation is
that shown in Figure 3B, in which PrP accumulation was not detectable at the terminal stage of disease). The brains of the animals of each genotype
were examined at the terminal stage of the disease. (A) Vacuolar changes were detected in both grey and white matter regions of the brain. The
heterozygous mice (101PL) had more vacuolation than the other two groups in a number of areas including the thalamus: (i) 101LL and (ii) 101PL.
Vacuolation in white matter was detected in all three genotypes but was most severe in the 101LL mice in the midbrain white matter, (iii) 101LL
and (iv) 101PP, and in the cerebral peduncle, (v) 101LL and (vi) 101PP. Bar, 100 µm. (B) PrP detected by immunocytochemistry in the brains of the
three genotypes of mice at the terminal stages of disease using polyclonal antibodies 1A8 (not shown) and 1B3. (i) The hippocampal region in
101PP mouse showed extensive neuronal loss of the CA1 pyramidal layer and PrP deposition in the corpus collosum. (iii) Minor CA1 pyramidal
neuronal loss and minimal deposits of PrP in the corpus collosum were detected in the heterozygous (101PL) mice whereas in the 101LL mice
(v) there was no evidence of CA1 neuronal loss and only minimal PrP accumulation was detected. (ii) Extensive PrP accumulation was detected in
restricted areas of the thalamus in 101PP mice. (iv) Lower levels were detected throughout the thalamic region of the 101PL mice, and (vi) in the
101LL mice extensive PrP deposition was detected throughout the thalamus. Bar, 100 µm.
inoculated with a number of different strains of scrapie
(Bruce et al., 1991) although not when inoculated with
ME7. The prolonged incubation periods in the mutant
mice may be due in part to the reduced level of PrP, but
this is unlikely to account for such long incubation periods
(Manson et al., 1994) and the mutation must also be
having a direct effect on the length of incubation time.
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The ME7-infected wild-type (101PP) mice had diffuse
PrP deposits throughout the brain (Figure 5) and vacuola-
tion was also observed in all regions of the brain
(Figure 2C). Marked neuronal loss was observed in
the CA1 region of the hippocampus. In contrast, the
neuropathology in the 101LL mice infected with ME7
was more restricted in terms of both vacuolation101L PrP mutation and TSE disease
Fig. 5. 101LL mice have long incubation times with ME7. Mice with
one and two copies of the Prnpa101L allele and wild-type mice were
inoculated with ME7 passaged in Sinc s7 mice. The brains of animals
of each genotype were examined at the terminal stage of the disease.
PrP detected by immunocytochemistry in the brains of the mice at the
terminal stages of disease using polyclonal antibodies 1A8 (not
shown) and 1B3. Diffuse deposits of PrP were detected throughout the
brain in the 101PP mice (i) in the thalamus (101PP) and (ii) the
hippocampus and corpus callosum (101PP), whereas in the 101LL
mice PrP deposition showed a more restricted pattern (iii) with
extensive accumulation in some areas of the thalamus (101LL) and
(iv) a large number of PrP aggregates along the entire length of the
corpus callosum (101LL). Bar, 100 µm.
(Figure 2C) and PrP deposition (Figure 5). In 101LL
mice, diffuse extracellular PrP was most notable in the
thalamus and hypothalamus. A large number of PrP
aggregates were seen along the entire length of the corpus
callosum and diffuse aggregates were observed in all
cortical layers. Neuronal loss was evident in the hippocam-
pal CA1 pyramidal cell layer but not to the same extent
as that observed in the wild-type mice. PrPSc was detected
by Western blot analysis in all three genotypes with wild-
type mice (101PP) showing quantitatively more PrPSc than
mice carrying one or two copies of the Prnpa101L allele
(101PL and 101LL) (Figure 6D).
The different disease proﬁles in the 101PP and 101LL
mice may result from different PrP alleles targeting
pathologyto differentbrainregions,although suchextreme
differencesinpathologyhavenotbeenobservedpreviously
between wild-type PrP alleles. Alternatively, these mice
may have selected a variant strain of ME7, as has
been observed previously for another scrapie strain after
changing the genotype of the mouse in which it was
passaged (Bruce and Dickinson, 1987). These possibilities
are currently under investigation.
Discussion
On the basis of a number of family studies, GSS, linked to
the 102L mutation in human PrP, has been described as
a genetic disease with an autosomal dominant mode of
inheritance and high penetrance (Hsiao et al., 1989; Speer
et al., 1991). Introduction of this mutation in situ into one
orbothoftheendogenousmurinePrPgeneshasnotresulted
in an inheritable spontaneous TSE in mice. Perhaps differ-
ences in other amino acids between the mouse and human
PrPsblockthespeciﬁceffectsofthehuman102Lappearing
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Fig. 6. Western analysis of brain homogenates for PrPSc using 8H4
monoclonal antibody. (A) Brains of uninoculated mice: lanes 1 and 2,
101PL (794 days old); lanes 3 and 4, 101PL (806 days old); lanes 5
and 6, 101PL (807 days old); lanes 7 and 8, 101LL (806 days old);
lanes 9 and 10, 101LL (815 days old); lanes 11 and 12, 101LL
(812 days old). Lanes 1, 3, 5, 7, 9 and 11 are treated with 20 µg/ml
proteinase K; lanes 2, 4, 6, 8, 10 and 12 are samples without
proteinase K. Exposure times of 10 s (top) and 10 min (bottom) are
shown to demonstrate the absence of PrPSc in these samples. (B) Mice
of each genotype inoculated with brain homogenate from a GSS
patient with the 102L mutation. Lanes 1 and 2, 101PP with no clinical
TSE; lanes 3 and 4, 101PL with no clinical TSE; lanes 5 and 6,
101PL with clinical TSE; lanes 7 and 8, 101LL at the terminal stage
of disease; lanes 9 and 10, 101LL at the terminal stage of disease;
lanes 11 and 12, uninfected 101PP; lanes 13 and 14, uninfected
101LL; lanes 15 and 16, uninfected PrP null mice. Lanes 1, 3, 5, 7, 9,
11, 13 and 15 are samples digested with 20 µg/ml proteinase K;
lanes 2, 4, 6, 8, 10, 12, 14 and 16 are samples without proteinase K.
Two different exposure times of the Western blot are shown: 10 s
(top) and 10 min (bottom). (C) Mice of each genotype inoculated with
brain homogenate from a mouse primarily infected with human GSS
at the terminal stage of disease (GSSLL). Lanes 1 and 2, 101LL;
lanes 3 and 4, 101PL; lanes 5 and 6, 101PP. Lanes 1, 3 and 5 are
digested with 20 µg/ml proteinase K; lanes 2, 4 and 6 are without
proteinase K. (D) Mice of each genotype infected with ME7. Lanes 1
and 2, 101PP; lanes 3 and 4, 101PL; lanes 5 and 6, 101LL. Lanes 1, 3
and 5 are digested with 20 µg/ml proteinase K; lanes 2, 4 and 6 are
without proteinase K.
as a disease in mice. On the other hand, in previous studies,
overexpression of PrP from multiple copies of a murine–
hamster chimeric gene carrying the 101L mutation led to a
spontaneous neurodegenerative disease in mice (Hsiao
et al., 1990; Hsiao et al., 1994; Telling et al., 1996). It may
be that the lifetime of a mouse carrying only one or two
copies of the mutant gene is not long enough to enable the
stochastic event that results in TSE disease to occur. If this
isthecase,itwouldbearguedthatthefamilialTSEdiseases
of humans could only be modelled in mice by overexpres-
sion of mutant PrP genes. This possibility cannot be ruled
out;however,wild-typelevelsofexpressionofamutantPrP
gene recently have been reported to lead to a spontaneous
neurological disease in mice (Chiesa et al., 1998), sug-
gesting that high overall levels of expression of PrP are not
anabsoluterequirementforthedevelopmentofspontaneous
disease. Multiple factors may be involved in triggering the
diseaseprocess, someofwhich maybedetermined bylocal
concentrations of PrP in different cell compartments and
thesemaydifferasaresultofvariationsintheprocessingof
PrP expressed from different Prnp alleles. Whether disease
resulting from general or local overexpression of PrP is
triggered by the same mechanism in mice as normal levels
of expression, remains to be established. That different
processes may be operating is suggested by the observationJ.C.Manson et al.
thatdiseaseinthehigh expressing101Lmicecouldonlybe
transmitted to mice that also carried the 101L transgene
(Hsiao et al., 1994), whereas the infectivity produced in
gene-targeted 101LL mice inoculated with GSS, described
here,wasreadilytransmissibletowild-typemiceinaddition
to those with Prnpa101L alleles.
The prion hypothesis, supported by PrP structural ana-
lysis, predicts that certain mutations in PrP may result in
unstable PrP molecules that are more likely to convert
from a normal cellular PrPC to the abnormal PrPSc, thus
initiating the disease process (Cohen et al., 1994; Huang
et al., 1994; Prusiner, 1997). The 102L mutation, in
common with a number of other mutations associated
with human disease, resides in the apparently unstructured
N-terminal region of the PrP protein. The structural
importanceofthisregionofPrPmayrelatetoitsinteraction
witheitherotherpartsofthePrPproteinorothermolecules.
It has been suggested that altered processing of mutant
PrP molecules or alterations in biochemical properties
following synthesis may render the protein infectious
(Harris and Lehmann, 1996). In vitro studies using a
recombinant PrP with the 101L mutation did not detect
alterations in stability properties (Swietnicki et al., 1998),
but alterations in secondary structure have been observed
when a recombinant 101L PrP protein was compared with
a recombinant wild-type PrP protein (Cappai et al., 1999).
While introduction of this mutation into the murine gene
described here has apparently led to a reduction in PrP
protein levels in the 101LL mice, which might be consist-
ent with altered processing or stability of the mutant
protein, these studies have not provided any biological
evidence for gross ‘instability’ of the PrP protein. Indeed
when the mutant mice were challenged with the ME7
strain of scrapie, the incubation time to clinical disease
was signiﬁcantly longer than in the wild-type mice and
could not be accounted for simply by reduced levels of
PrPC. This suggests that the 101L PrP protein replicates
ME7 infectivity more slowly than the wild-type PrP.
The introduction of the 101L mutation into the murine
PrP gene has dramatically altered the incubation period
of TSEs in the mice that carry the mutant gene. Challenge
with an inoculum from a GSS102L patient has led to
disease developing in all the mice carrying two copies of
this mutation in only 288 days. The presence of the 101L
mutation in the murine gene is sufﬁcient to render animals
highly susceptible to disease when challenged with brain
homogenate from a GSS case. Transmission of infectivity
from one species to another usually results in disease in
only a low percentage of animals and with a wide range
of incubation times on primary passage. The difﬁculty of
transmitting TSE disease between two species is known
as the ‘species barrier’ (Dickinson, 1976). This barrier
was observed when wild-type 101PP mice were inoculated
with brain material from a GSS patient, with only one out
of eight animals developing clinical signs of TSE. In
contrast, all the 101LL mice succumbed to disease with
similar incubation periods when inoculated with GSS,
indicating that the introduction of a single point mutation
into the endogenous murine PrP gene has removed a
major part of the human to mouse species barrier with
GSS infectivity. The remarkably short incubation periods
for GSS in the 101LL mice have not been observed when
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these mice have been inoculated with other sources of
human TSE (experiments in progress).
The results presented here suggest that rather than
producing a spontaneous transmissible disease, the substi-
tution of proline by leucine at amino acid 101 in the
murine PrP gene renders the animals that carry it more
susceptible to human GSS while increasing incubation
time with ME7. This altered response is comparable to
that observed following switching of codons at 108 and
189 in the murine gene (Moore et al., 1998). Our ﬁndings
are therefore consistent with the idea that humans carrying
102L may have increased susceptibility to speciﬁc strains
of TSE infection (e.g. GSS), rather than succumbing to a
spontaneous disease, i.e. an apparent genetic disease may
be caused by a high susceptiblity to a ubiquitous agent.
The identiﬁcation of PrPSc in the brain and other tissues
is often taken as a deﬁnitive marker of TSE disease. In
many TSEs, a close correlation exists between the level
of infectivity and the level of PrPSc. There are, however,
a number of examples in which the particular character-
istics of disease are not associated with high levels of
PrPSc (Hsiao et al., 1994; Lasmezas et al., 1997; Hedge
et al., 1998). Nevertheless, the apparent absence of PrPSc
has been equated with a low titre or absence of infectivity.
Several animals carrying the 101L mutation and showing
clinical signs following infection with human GSS
inoculum had extremely low levels of PrP. The deposition
of PrP in the brains of these animals was barely detectable
despite extensive immunocytochemical analysis and was
only detected by Western blot analysis following long
exposure times. Brain material from one of the mice
succumbing to disease after challenge with the human
GSS source was inoculated into both transgenic (101PL
and 101LL) and non-transgenic (101PP) mice, and disease
developed rapidly in all recipients. The low level of PrPSc
detected by Western blot analysis in the brain of a 101LL
mouse on ﬁrst passage with GSS (Figure 6B) would
correspond to a very low titre of infectivity in other well-
characterized murine models of scrapie and would be
associated with long incubation times on subsequent
passage in mice. Without a full titration (which is now in
progress), we are unable to show formally that there is a
high titre of infectivity in the ﬁrst passage brain, but the
short incubation periods in mice receiving this inoculum
would suggest that a high titre of infectivity was present
in this brain with very low levels of PrPSc. Apparently,
the lack of detectable PrPSc in a tissue may not always
represent a reliable marker for the absence of TSE
infection.
Materials and methods
Generation of the mice heterozygous and homozygous for
the Prnpa101L allele
PrP codon 101 alteration was introduced into HM-1 ES cells as described
(Moore et al., 1995). Brieﬂy, the gene-targeting vector was constructed
using isogenic 129/Ola Prnpa exon 3-ﬂanking sequence derived from an
HM-1 genomic library in λ DASH II (Stratagene). PrP codon 101
alteration was introduced into a 934 bp KpnI–EcoRI exon 3 fragment
containing the open reading frame (ORF) by the Kunkel method (Kunkel
et al., 1987) and ligated in a single step with 5 and 3 homologous
sequence derived from p129PrP, a 8.5 kb BamHI genomic clone spanning
129/Ola exon 3. The ORF encoding PrP in the targeting vector was
sequenced immediately prior to use and this conﬁrmed the presence of
the desired Prnp alterations and the absence of cloning artefacts or other101L PrP mutation and TSE disease
mutations. 129/Ola HM-1 ES cells with the targeted Prnpa101L allele
were introduced into BALB/c 3.5 day blastocysts and transferred to
pseudopregnant MF1 recipients as described (Thompson et al., 1989).
Chimeras were mated with inbred 129/Ola (129/OlaHsd, Harlan, UK)
and germline pups were investigated for the targeted allele by PCR.
129/Ola littermates heterozygous for the targeted allele were crossed to
generate mice homozygous for the Prnpa101L allele. All mice encoded
only the wild-type HPRT alleles (Thompson et al., 1989). The Prnp
coding region from 101LL mice was sequenced. The entire ORF was
generated by PCR, cloned into a pGEM-T vector (Promega), and plasmid
DNA was isolated and sequenced (Sequenase, Amersham).
PCR genotyping of mouse tail DNA
A 765 bp fragment containing the entire Prnp ORF was generated using
a5  primer (5-ATGGCGAACCTTGGCTACTGGCTG-3; position
107–130, DDBJ/EMBL/GenBank accession No. M18070) and a 3
primer (5-TCATCCCACGATCAGGAAGATGAG-3; position 871–848,
DDBJ/EMBL/GenBank accession No. M18070. Cycle conditions were:
94°C for 3 min, followed by 30 cycles of 30 s at 94°C ,3 0sa t6 2 °C
and 1 min at 72°C. This was followed by a ﬁnal 10 min at 72°C
(Biometra Triblock). The presence or absence of a DdeI site within the
PCR product provided a marker for the codon 101P–L alteration.
Southern analysis of PrP gene
Genomic DNA was prepared by lysis of brain tissue (10 mM Tris–HCl
pH 7.6, 10 mM EDTA, 0.5% sarcosyl, 10 mM NaCl and 100 µg/ml
proteinase K) overnight at 37°C. The lysate was extracted in phenol
followed by phenol:cholorform (1:1) and precipitated with isopropanol
and resuspended in TE buffer. Following restriction (10 µg of DNA), the
DNAfragmentswereseparatedon1%agaroseandblottedontoGenescreen
Plus (Dupont). Hybridization was carried out at 65°C overnight using a
700 bp EcoRV–BamHI fragment (3 probe) and a 884 bp PCR product
(Figure 1) as probes. Following stringent washing procedures (0.1 SSC
at 65°C), the blots were exposed to X-ray ﬁlm for 2 days.
TSE inoculum and challenge
BrainmaterialwasobtainedfromaGSSpatient.Genotypinghadconﬁrmed
the presence of the 102L mutation in one of the alleles of the PrP gene of
this patient. The brain material was homogenized (1:10 and 1:100) in
normal saline prior to inoculation. Brain material from a 101LL mouse
terminallyinfectedwith GSSandfromthemurinescrapie strainofscrapie
ME7 were homogenized (1:100) prior to use as inoculum (Fraser and
Dickinson, 1968). Mice were coded and genotyped before intracerebral
injection with 20 µl of inoculum under halothane anaesthesia. Scoring for
signs of illness was performed as described (Dickinson et al., 1968). Mice
weregenotypedagainatpost-mortem.Allanalysisofthemicewascarried
out prior to decoding the experiment. Incubation periods were calculated
as the interval between inoculation and terminal illness.
Lesion proﬁles
Mice were killed by cervical dislocation at the terminal stage of disease.
The brains were removed and ﬁxed in 10% formol saline. H&E-stained
coronal sections (6 µm) at four levels were scored for vacuolar degenera-
tion on a scale of 0–5 in nine standard grey matter areas and three standard
white matter areas as described (Fraser and Dickinson, 1967, 1968).
PrP immunocytochemistry
Mice were killed by cervical dislocation at the terminal stage of disease.
Brainswereremovedandimmersion-ﬁxedfor48hinformolsaline(10%).
Fixation was followed by decontamination for 1 h in formic acid (98%).
The brains were then dehydrated with alcohol and impregnated in wax
during a 7 h processing cycle. Microtome sections (6 µm) were cut and
mounted on Superfrost plus slides. Sections were immunostained by the
standard peroxidase–anti-peroxidase (PAP) method using two polyclonal
antisera to PrP: 1B3 (Farquhar et al., 1989) (1:1000 overnight at room
temperature) and 1A8 (Farquhar et al., 1993) (1:4002ha troom temper-
ature). The reaction product was visualized with diaminobenzidine and
sections were counterstained lightly with haematoxylin.
Western blotting
For the detection of PrPSc in transgenic and wild-type mice, 10% (w/v)
homogenates of brain tissue were prepared in NP-40 buffer [0.5% (v/v)
NP-40, 0.5% (w/v) sodium deoxycholate, 150 mM NaCl, 50 mM Tris–
HCl pH 7.5]. Homogenates were centrifuged at 11 000 g for 15 min at
10°C to remove cellular debris. Supernatant samples (100 µl) were incub-
ated with or without proteinase K (20 µg/ml) for 1 h at 37°C, and the





brane by electroblotting, and incubated with either monoclonal antibody
8H4(Zanussoetal.,1998)orpolyclonalrabbitserum1A8(Farquharetal.,
1993) for 2 h at room temperature. Proteins were visualized with either
horseradish peroxidase (HRP)-conjugated rabbit anti-mouse or HRP-
conjugatedgoatanti-rabbit,andachemiluminescencedetectionkit(Roche
Diagnostics). Membranes were exposed to X-ray ﬁlm for periods ranging
from 10 s to 10 min.
Northern analysis of mRNA from the Prnpa101L allele
TotalRNAwasisolatedusingRNAzol™B(Biogenesis,Poole,UK)based
on the guanidinium thiocyanate–phenol–chloroform extraction method
(Chomczynski and Sacchi, 1987). A 20 µg aliquot of total RNA was
separated on a 1.0% agarose–formaldehyde denaturing gel, transferred to
Hybond N (Amersham Pharmacia Biotech, UK) and probed with a 32P-
labelled 936 bp KpnI–EcoRI fragment from exon 3 of Prnp.
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